Omeros Corporation

NASDAQ:OMER   3:59:58 PM EDT
6.25
-0.50 (-7.41%)
Products

FDA Grants Orphan Drug Designation To Omeros' MASP-3 Inhibitor OMS906 For Treatment Of Paroxysmal Nocturnal Hemoglobinuria

Published: 07/29/2022 13:09 GMT
Omeros Corporation (OMER) - FDA Grants Orphan Drug Designation to Omeros’ Masp-3 Inhibitor Oms906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria.
Omeros - Expects to Begin Enrollment This Summer in Trial Assessing Oms906 in Pnh Patients With Unsatisfactory Response to C5 Inhibitor Ravulizumab.
Omeros Corp - is Also Targeting Efficacy Data in Populations of Treatment-naÏve Pnh and C3 Glomerulopathy Patients by Early 2023.
Omeros - Administration of Oms906 Expected to Be Once Monthly to Once Quarterly Intravenously Or Subcutaneously.